Table 1. Investigational medical... | American Society of Hematology

Table 1.

Investigational medical therapies for the BCR-ABL–negative myeloproliferative disorders.

Disease	Agent	Class/type of drug	Route	Phase	Reference
Abbreviations: PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; MF, myelofibrosis; IV, intravenous; SQ, subcutaneous; TGF, tumor growth factor; VEGF, vascular endothelial growth factor
		Immunomodulatory agents
PV/ET	Pegylated interferon-2a	Immunomodulatory agent	SQ	2	22
PMF/post-ET/PV MF	Lenalidomide + prednisone	Immunomodulatory agent	Oral	2	43
PMF/post-ET/PV MF	CC-4047 ± prednisone	Immunomodulatory agent	Oral	2	Ongoing
		Targeting the stromal reaction
PMF/post-ET/PV MF	GC-1008	Pan-specific human	IV	2	44
		anti–TGF-β antibody
PMF/post-ET/PV MF	Bevacizumab	Anti-VEGF monoclonal antibody	IV	2	45
		DNA hypomethylating agents
PMF/post-ET/PV MF	Azacitidine	Hypomethylating agent	SQ	2	Ongoing
PMF/post-ET/PV MF	Decitabine	Hypomethylating agent	IV	2	Ongoing
		Targeting apoptosis agents
PMF/post-ET/PV MF	Bortezomib	Proteasome inhibitor	IV	2	46
		Kinase inhibitory agents
PMF/post-ET/PV MF	Dasatinib	Kinase inhibitor	Oral	2	47
		JAK2 inhibitors in development
PMF/post-ET/PV MF (at first)	TG 101209	JAK2 inhibitor	Oral	1/2	37
PMF/post-ET/PV MF (at first)	Go6976	FLT3-JAK2 inhibitor	Unknown	Preclinical	38
PMF/post-ET/PV MF (at first)	Erlotinib	JAK2 inhibitor	Oral	1/2	39
PMF/post-ET/PV MF (at first)	MK 0457	Aurora kinase inhibitor	IV	1/2	40
PMF/post-ET/PV MF (at first)	CEP-701	FLT3-JAK2 inhibitor	Oral	1/2	41

Disease	Agent	Class/type of drug	Route	Phase	Reference
Abbreviations: PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; MF, myelofibrosis; IV, intravenous; SQ, subcutaneous; TGF, tumor growth factor; VEGF, vascular endothelial growth factor
		Immunomodulatory agents
PV/ET	Pegylated interferon-2a	Immunomodulatory agent	SQ	2	22
PMF/post-ET/PV MF	Lenalidomide + prednisone	Immunomodulatory agent	Oral	2	43
PMF/post-ET/PV MF	CC-4047 ± prednisone	Immunomodulatory agent	Oral	2	Ongoing
		Targeting the stromal reaction
PMF/post-ET/PV MF	GC-1008	Pan-specific human	IV	2	44
		anti–TGF-β antibody
PMF/post-ET/PV MF	Bevacizumab	Anti-VEGF monoclonal antibody	IV	2	45
		DNA hypomethylating agents
PMF/post-ET/PV MF	Azacitidine	Hypomethylating agent	SQ	2	Ongoing
PMF/post-ET/PV MF	Decitabine	Hypomethylating agent	IV	2	Ongoing
		Targeting apoptosis agents
PMF/post-ET/PV MF	Bortezomib	Proteasome inhibitor	IV	2	46
		Kinase inhibitory agents
PMF/post-ET/PV MF	Dasatinib	Kinase inhibitor	Oral	2	47
		JAK2 inhibitors in development
PMF/post-ET/PV MF (at first)	TG 101209	JAK2 inhibitor	Oral	1/2	37
PMF/post-ET/PV MF (at first)	Go6976	FLT3-JAK2 inhibitor	Unknown	Preclinical	38
PMF/post-ET/PV MF (at first)	Erlotinib	JAK2 inhibitor	Oral	1/2	39
PMF/post-ET/PV MF (at first)	MK 0457	Aurora kinase inhibitor	IV	1/2	40
PMF/post-ET/PV MF (at first)	CEP-701	FLT3-JAK2 inhibitor	Oral	1/2	41